Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that LRP11-AS1 knockdown suppresses papillary thyroid cancer progression via the miR-615-3p/AKT2 axis, highlighting a potential therapeutic target.
• Patients with papillary thyroid cancer (PTC) who experience local recurrence and distant metastases have a poor clinical prognosis and low survival rate. • Significant overexpression of LRP11-AS1 was observed in both PTC tissues and PTC cell lines. • Inhibitory effects of LRP11-AS1 knockdown on the growth and migration of PTC cells were verified. • LRP11-AS1 exhibited potential oncogenic effects in PTC by regulating the miR-615-3p/AKT2 axis. Patients with papillary thyroid cancer (PTC) who experience local recurrence and distant metastases have a poor clinical prognosis and low survival rate. In this study, the expression of LRP11-AS1 was evaluated in both tissue samples from patients with papillary thyroid cancer and in PTC cell lines. We observed significant overexpression of LRP11-AS1 in both PTC tissues and PTC cell lines and inhibitory effects of LRP11-AS1 knockdown on the growth and migration of PTC cells. Mechanistically, knockdown of LRP11-AS1 led to upregulation of miR-615-3p, overexpression of miR-615-3p decreased the expression of both LRP11-AS1 and AKT2. The dual-luciferase reporter assay confirmed the inhibitory effect of miR-615-3p on the expression of LRP11-AS1 and AKT2. Knockdown of LRP11-AS1 inhibited in vivo growth of PTC tumor in nude mice model. LRP11-AS1 exhibited potential oncogenic effects in PTC by regulating the miR-615-3p/AKT2 axis, suggesting that LRP11-AS1 could serve as a potential diagnostic biomarker and therapeutic target in PTC.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: